文献速递肝病消化道肿瘤与早癌

索拉非尼靶向毒性可预测肝细胞癌患者生存改善:一项多中心前瞻性研究

On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study.
PubMed 文献 · Aliment Pharmacol Ther · 2017-03-02

在这项多中心前瞻性队列研究中,共纳入634例接受索拉非尼治疗的晚期肝细胞癌患者,中位随访6692.3人月。多因素分析显示,索拉非尼相关腹泻(HR 0.76)、高血压(HR 0.531)和手足综合征(HR 0.65)均为总生存期的显著独立预测因素。

要点

  • 634例晚期肝细胞癌患者接受索拉非尼治疗,中位生存期8.1个月。
  • 索拉非尼相关腹泻、高血压和手足综合征与总生存期延长独立相关。
  • 94%患者出现至少一种索拉非尼相关毒性,21%因毒性停药。

核心结论

  • 索拉非尼相关毒性(包括腹泻、高血压和手足综合征)与接受索拉非尼治疗的晚期肝细胞癌患者总生存期延长相关。

研究设计与样本

  • 多中心前瞻性队列研究,从五个国际专科中心招募接受索拉非尼治疗的晚期肝细胞癌患者,前瞻性记录人口学与临床数据、治疗期间索拉非尼毒性的发生与分级、影像学疗效及生存时间(月)。

主要发现

  • 共纳入634例晚期肝细胞癌患者,中位随访6692.3人月;大多数为男性(81%)、Child-Pugh A级肝病(74%)、巴塞罗那临床肝癌分期C期(64%)。
  • 中位生存期为8.1个月(IQR 3.8-18.6个月)。
  • 94%患者经历至少一种索拉非尼相关毒性:34%腹泻、16%高血压、37%手足综合征(HFS)。
  • 21%因毒性停用索拉非尼,59%因疾病进展或死亡停止治疗。
  • 多因素分析显示,索拉非尼相关腹泻(HR 0.76,95% CI 0.61-0.95,P = 0.017)、高血压(HR 0.531,95% CI 0.37-0.76,P < 0.0001)和HFS(HR 0.65,95% CI 0.51-0.81,P < 0.0001)均为总生存期的显著独立预测因素(校正年龄、肝病严重程度、肿瘤分期和索拉非尼剂量后)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and has high mortality despite treatment. While sorafenib has a survival benefit for patients with advanced HCC, clinical response is highly variable. AIM: To determine whether development of sorafenib toxicity is a prognostic marker of survival in HCC. METHODS: In this prospective multicentre cohort study, patients with advanced-stage HCC receiving sorafenib were recruited from five international specialist centres. Demographic and clinical data including development and grade of sorafenib toxicity during treatment, radiological response to sorafenib and survival time (months) were recorded prospectively. RESULTS: A total of 634 patients with advanced-stage HCC receiving sorafenib were recruited to the study, with a median follow-up of 6692.3 person-months at risk. The majority of patients were male (81%) with Child-Pugh A stage liver disease (74%) and Barcelona Clinic Liver Cancer stage C HCC (64%). Median survival time was 8.1 months (IQR 3.8-18.6 months). 94% experienced at least one sorafenib-related toxicity: 34% diarrhoea, 16% hypertension and 37% hand-foot syndrome (HFS). Twenty-one per cent ceased sorafenib due to toxicity and 59% ceased treatment due to progressive disease or death. On multivariate analysis, sorafenib-related diarrhoea (HR 0.76, 95% CI 0.61-0.95, P = 0.017), hypertension (HR 0.531, 95% CI 0.37-0.76, P < 0.0001) and HFS (HR 0.65, 95% CI 0.51-0.81, P < 0.0001) were all significant independent predictors of overall survival after adjusting for age, severity of liver disease, tumour stage and sorafenib dose. CONCLUSION: Development of sorafenib-related toxicity including diarrhoea, hypertension and hand-foot syndrome is associated with prolonged overall survival in patients with advanced-stage HCC on sorafenib.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Howell J, Pinato DJ, Ramaswami R, et al. On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study. Aliment Pharmacol Ther. 2017. PMID: 28252185. doi:10.1111/apt.13977

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。